Can you predict which pts with #PsA #psoriatic #arthritis Will respond to #TNFi #Rx? Well, 🤔 maybe Needs validation and an easy reliable inexpensive biomarker! #EULAR2024 @RheumNow @eular_org POS0992 https://t.co/Ce92561AMO

• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1
• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1

PsA: one composite index that does it all cDAPSA + Investigator’s Global Assessment (IGA) of PSO Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA 88% sensitivity & specificity in DISCOVER-1 & 2 trial data #EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC

• https://twitter.com/AurelieRheumo/status/1801513887650435431/photo/1

🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer 38 PSO patients w/ arthralgia Correlation PET/CT SUVmax, TJC & tender enthesis count 68Ga-FAPI-04 uptake = higher risk developing PsA 6mo Shows signs of inflammation before MSUS! #EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn

• https://twitter.com/AurelieRheumo/status/1801509983638507885/photo/1

This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB

• https://twitter.com/i/web/status/1801510391878398397
• https://twitter.com/synovialjoints/status/1801510391878398397/photo/1

Did the patient fail on therapy or are the therapies failing the patient? 🤔 Difficult to to manage psoriatic arthritis: A suggested approach #EULAR2024 NZ https://t.co/lYvXEX7dp3

• https://twitter.com/ARD_BMJ/status/1800873396042924158/photo/1

New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz

• https://twitter.com/ARD_BMJ/status/1801179294271443086/photo/1

Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

• https://twitter.com/AurelieRheumo/status/1801230838136213897/photo/1

TYK2i RCT 290 pts 12 wks in active PSA TAK-279 15mg 30 mg 53% 54% vs PBO 29% ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15% Safety profile acceptable Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp

• https://twitter.com/AurelieRheumo/status/1801228048466870716/photo/1

12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB

• https://twitter.com/i/web/status/1801191845084463335
• https://twitter.com/synovialjoints/status/1801191845084463335/photo/1
• https://twitter.com/synovialjoints/status/1801191845084463335/photo/1